Browse by category

Treatment for obesity in the UK could become a two-tier system where the most vulnerable patients miss out altogether, obesity experts from King's College London and the Obesity Management Collaborative (OMC-UK) have warned. They stated that strict eligibility criteria means that only a small number of people will have access to the weight loss drug tirzepatide (Mounjaro) on the NHS, with those able to afford it paying privately for treatment. The researchers argue, in an edi

Patients weighing 450 pounds (lbs) or more face barriers and discrimination when scheduling or attending doctor visits at subspecialty...

In a recent cross-sectional study, researchers from Pennington Biomedical Research Center found that severe obesity is associated with a...

Improvements in the physical component of quality of life (QoL) after metabolic and bariatric surgery (MBS) varies for patients with...